MEDIZIN: Diskussion
Behandlung des kolorektalen Karzinoms mit monoklonalen Antikörpern: Nachfolgende immunologische Mechanismen
The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: Subsequent Immunological Mechanisms


Dr. med. A. G. Tsamaloukas
Schulstraße 16–18, 40721 Hilden
E-Mail: tsamaloukas@onkologe-hilden.de
1.
Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–7. MEDLINE
2.
Musolino A et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789–96. MEDLINE
3.
Bibeau F et al.: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122–9. MEDLINE
4.
Stintzing S, Heinemann V, Jung A, Moosmann N, Hiddemann W, Kirchner T: The treatment of colorectal carcinoma with monoclonal antibodies—the importance of KRAS mutation analysis and EGFR status [Behandlung des kolorektalen Karzinoms mit monoklonalen Antikörpern – Bedeutung der KRAS Mutationsanalyse und des EGFR-Status]. Dtsch Arztebl Int 2009; 106: 202–6. VOLLTEXT
1. | Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–7. MEDLINE |
2. | Musolino A et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789–96. MEDLINE |
3. | Bibeau F et al.: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122–9. MEDLINE |
4. | Stintzing S, Heinemann V, Jung A, Moosmann N, Hiddemann W, Kirchner T: The treatment of colorectal carcinoma with monoclonal antibodies—the importance of KRAS mutation analysis and EGFR status [Behandlung des kolorektalen Karzinoms mit monoklonalen Antikörpern – Bedeutung der KRAS Mutationsanalyse und des EGFR-Status]. Dtsch Arztebl Int 2009; 106: 202–6. VOLLTEXT |
Kommentare
Die Kommentarfunktion steht zur Zeit nicht zur Verfügung.